Every S-1 that GridAI Technologies Corp. (GRDX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow GRDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GRDX filings page.
GridAI Technologies Corp. (GRDX) filed an amended S-1 to register for resale up to 9,908,766 shares of common stock held by selling stockholders, including shares issuable on exercise of Pre-funded Warrants and Common Warrants from May and July 2026 private placements. GridAI itself is not selling shares and will only receive cash if warrants are exercised for cash.
The company focuses on AI-driven energy orchestration for data centers via Grid AI Corp. and legacy GI drug candidate Adrulipase. As of June 30, 2026, GridAI had $1.4 million in cash, an accumulated deficit of $224.9 million, negative working capital of $11.8 million, a $10.1 million goodwill impairment, and a forecast annual cash burn of $7.8 million. Auditors have expressed substantial doubt about its ability to continue as a going concern.
GridAI has raised or arranged gross proceeds of about $12.5 million across three 2026 private placements, with $4 million already received and $12.3 million contractually to be paid before this registration is effective. If the registration is not declared effective by January 2027, or if additional funding is not obtained, the company states it may need to curtail or cease operations, liquidate, or seek bankruptcy protection. Full conversion of its Series H preferred stock, if milestones and stockholder approval are achieved, would dilute pre-acquisition stockholders’ ownership by about 84.5%.
GridAI Technologies Corp. has filed an amended resale registration covering up to 9,908,766 shares of common stock, all to be sold by existing stockholders from Common Shares and warrants issued in May and July 2026 private placements. GridAI combines an AI-focused grid-optimization software business with a legacy Adrulipase biopharma program, both still in development.
The company will not receive proceeds from these resales, but may receive cash if investors exercise registered warrants. It reports cash and equivalents of $386,000 as of March 31, 2026 and a forecast annual cash burn of about $7.8 million. Together with roughly $4 million already received and an additional $12.3 million committed from the 2026 financings, management currently expects to fund planned operations for at least the next eighteen months, based on assumptions that may change.
Auditors have issued going concern opinions, and disclosures state that failure to secure capital or achieve effectiveness of this registration could force severe operational cuts, restructuring, or bankruptcy. GridAI also quantifies substantial potential dilution for existing holders from full warrant exercises and from possible future conversion of Series H preferred stock.
GridAI Technologies Corp. is registering 9,908,766 shares of common stock for resale by investors from its May and July 2026 private placements. The company itself will not receive proceeds from these sales, though it may receive cash if outstanding warrants are exercised.
GridAI operates a dual business: an energy orchestration and grid-optimization software platform for AI data centers through Grid AI Corp., and legacy biopharmaceutical development focused on Adrulipase. It has incurred significant losses, with an accumulated deficit of about $212.1 million and cash of $386,000 as of March 31, 2026, and its auditors have raised substantial doubt about its ability to continue as a going concern.
Recent private placements total roughly $7.8 million in May 2026 and $8.5 million in July 2026, much of which is payable before this registration becomes effective and tied to pre-funded and common warrants. The filing highlights that failure to secure additional financing or effectiveness of this registration by January 2027 could force the company to curtail or cease operations, pursue liquidation, or seek bankruptcy protection. It also discloses that if its Series H Preferred Stock becomes convertible, up to 38,801,546 new common shares could be issued, which would significantly dilute existing stockholders relative to the 6,913,241 shares outstanding as of July 2, 2026.
GridAI Technologies Corp. is registering 6,204,920 shares of common stock for resale by existing investors, including shares issuable from pre-funded and common warrants issued in May 2026 private placements. The company is not selling shares itself and will only receive cash if warrants are exercised.
GridAI operates AI-focused energy orchestration software through Grid AI Corp. and continues legacy Adrulipase drug development, but has generated limited revenue and remains loss-making. As of March 31, 2026, it held about $386,000 in cash, a working capital deficit of $13.7 million and an accumulated deficit of $212.1 million, and auditors have raised substantial doubt about its ability to continue as a going concern.
Recent financings on May 18, 2026 provided approximately $7.8 million in gross proceeds, which management expects to fund operations into the third quarter of 2026. GridAI is evaluating strategic options, including potential mergers, reverse mergers, asset sales, wind-down or bankruptcy, and plans to seek additional capital, including funding for a potential Phase 3 trial of Adrulipase.